Polaryx Therapeutics, Inc.
PLYX
$2.08
$0.062.97%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 62.01% | 280.65% | -5.90% | 10.31% | 25.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.11% | -61.24% | 26.00% | 26.33% | -29.39% |
| Operating Income | -56.11% | 61.24% | -26.00% | -26.33% | 29.39% |
| Income Before Tax | -36.90% | 49.64% | -106.78% | -85.47% | 19.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.90% | 49.64% | -106.78% | -85.47% | 19.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.90% | 49.64% | -106.78% | -85.47% | 19.49% |
| EBIT | -56.11% | 61.24% | -26.00% | -26.33% | 29.39% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -26.55% | 52.68% | -73.37% | -53.69% | 36.87% |
| Normalized Basic EPS | -26.95% | 52.67% | -73.04% | -53.54% | 37.05% |
| EPS Diluted | -26.55% | 52.68% | -73.37% | -53.69% | 36.87% |
| Normalized Diluted EPS | -26.95% | 52.67% | -73.04% | -53.54% | 37.05% |
| Average Basic Shares Outstanding | 8.08% | 6.50% | 19.39% | 20.48% | 27.89% |
| Average Diluted Shares Outstanding | 8.08% | 6.50% | 19.39% | 20.48% | 27.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |